Clinical observation of sintilimab combined with bevacizumab in the treatment of advanced unresectable liver cancer after transcatheter arterial chemoembolization
OBJECTIVE To observe the efficacy,tumor markers,immune function and safety of sintilimab combined with bevacizumab in the treatment of advanced unresectable hepatocellular carcinoma(HCC)after transcatheter arterial chemoembolization(TACE).METHODS A total of 120 patients with advanced unresectable HCC in No.901 Hospital of Joint Service Support Force of PLA from June 2022 to December 2022 were selected and divided into control group(n=60)and study group(n=60)using the random number method.Both groups received TACE.The control group was treated with Sorafenib mesylate tablets,and the study group was treated with Sintilimab injection combined with Bevacizumab injection.The clinical efficacy,tumor markers(alpha-fetoprotein,carcinoembryonic antigen,carbohydrate antigen 19-9),immune function indexes(CD3+,CD4+,CD8+,CD4+/CD8),and adverse reactions of the two groups were observed after three months of treatment.RESULTS After the treatment,there was no significant difference between the two groups in objective remission rate,disease control rate,mortality rate,or median progression-free survival(P＞0.05).The median overall survival of the study group was significantly longer than control group(P＜0.05).After treatment,the levels of tumor markers and immune function(except for CD8)in both groups were significantly lower than before treatment;the average levels of tumor markers in the study group were significantly lower than control group,while the levels of immune function(except for CD8)were significantly higher than control group(P＜0.05).There was no statistically significant difference in the incidence of grade 3 adverse reactions,as well as the incidence of grade 1-2 adverse reactions such as hypothyroidism and immune-related pneumonia between the two groups(P＞0.05).CONCLUSIONS For advanced unresectable HCC patients undergoing TACE,bevacizumab combined with sintilimab can effectively improve immune function,reduce tumor markers and improve the overall survival with good safety.
hepatocellular carcinomaadvanced unresectablesintilimabbevacizumabtranscatheter arterial chemoemboli-zationefficacyimmune function
万方数据
维普
